Company Wayland Group Corp Canadian Securities Exchange
Equities
CA5667241007
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2016 | Weight | 2017 | Weight | Delta |
---|---|---|---|---|---|
Marijuana Production for Medical Purposes
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -18.98% |
Sales per region
USD in Million | 2016 | Weight | 2017 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -18.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | - | |
Geoff Kosar
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 237,260,499 | 237,260,499 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Wayland Group Corp.
845 Harrington Court Unit 3
L7N 3P3, Burlington
+289-288-6274
Sector
1st Jan change | Capi. | |
---|---|---|
+39.33% | 6.11B | |
-18.38% | 4.35B | |
-9.17% | 3.18B | |
+3.98% | 3.16B | |
-3.41% | 2.51B | |
+48.74% | 1.98B | |
-4.82% | 1.74B | |
-1.24% | 1.63B | |
-8.96% | 1.6B |